Lung cancer is the number one killer of cancers in the world, and its incidence and mortality rate rank first among malignant tumors, seriously threatening human life and health. From targeted therapy to immunotherapy, lung cancer has been fully managed. In order to better serve the majority of patients, vigorously promote "Internet +" online services, and effectively solve the problems of esophageal cancer diagnosis and treatment encountered in various clinical departments through online communication, Chengdu High-tech Medical Association successfully held two academic forums on lung cancer immunity online from August to November 2022.

Experts from the meeting covered experts from West China Hospital of Sichuan University, Yunnan Cancer Hospital, Zhongnan Hospital of Wuhan University, Affiliated Hospital of North Sichuan Medical College, Cancer Hospital Affiliated to Chongqing University and Tongji Hospital Affiliated to Huazhong University of Science and Technology. All the participating experts carried out an inspiring collision of ideas in the form of academic conferences and case sharing.

The conference invited well-known experts in the field of lung cancer from various provinces across the country to give lectures, focusing on topics such as adverse reactions caused by breast lung cancer treatment and chemotherapy, and building a platform for exchange and learning for experts and colleagues in the form of academic lectures and case discussions. It provides a platform for the exchange of diagnosis and treatment technology and academic scientific research results for the majority of clinical medical practitioners and scientific research workers.